China Biologic Products Holdings Profit Margin

China Biologic Products Holdings posts a profit margin of 29.04% as of December 2020. That compares with 27.22% in the prior-year period — up 6.7% year over year. That is above the Healthcare sector average of 14.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Biologic Products Holdings's profit margin was 27.22%. The latest reading is 29.04% — a 6.7% year-over-year increase (period ending December 2020). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 14.34% is typical. China Biologic Products Holdings's 29.04% is higher that level. That is roughly 102.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

China Biologic Products Holdings's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 29.04% as of December 2020; use YoY and peer views to separate noise from signal.

Context for CBPO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 14.34%), and (3) consistency with growth and profitability. This page covers the first two; China Biologic Products Holdings's other metric pages and overview cover the third.